Refractory Depression Management

Aka: Refractory Depression Management, Depression Unresponsive to Medication, Treatment-Resistant Depression

advertisement

II. Definitions

  1. Treatment-Resistant Depression
    1. Persistence of Major Depression using validated scoring tools AND
    2. Two or more Antidepressant medications trialed at adequate dose, duration and adherance
  2. Partial Treatment Response
    1. Major Depression rating scores improve <50% with treatment

III. Epidemiology

  1. Treatment-Resistant Depression occurs in nearly one third of Major Depression patients

IV. Risk Factors: Treatment-Resistant Depression

  1. Multiple comorbid conditions (e.g. cardiovascular disease)
  2. Major Depression onset at an early age
  3. Childhood Trauma
  4. Comorbid mental health disorder
    1. Substance Use Disorder
    2. Anxiety Disorder
    3. Personality Disorder

V. Management: Step 1

  1. Evaluate for Suicidality and other conditions requiring emergency care
  2. Assess Major Depression Differential Diagnosis
    1. Consider Bipolar Disorder (present in in up to 25% of Mood Disorder patients in primary care)
  3. Maximize non-medication therapies (e.g. Exercise, psychotherapy)
    1. See Depression Management
    2. Structured Exercise program (aerobic and Resistance Training)
    3. Psychotherapy
  4. Assess Adequacy of Antidepressant trial
    1. Minimum Duration: 6-8 weeks
    2. Minimum Dose: one dose increase at 2-4 weeks
  5. Assess for comorbid confounding factors
    1. Anxiety Disorder
    2. Increased Psychosocial Stressors
    3. Alcohol or Drug Abuse
    4. Excessive Caffeine intake
    5. Chronic medical illness
    6. Medications Predisposing to Depression
  6. Assess Compliance
    1. Medication nonadherance occurs in almost half of patients with Major Depression
    2. Has patient abruptly discontinued Antidepressant
    3. Has patient missed or skipped Antidepressant doses
    4. Has Antidepressant been temporarily interrupted
      1. Missed medication refill
      2. Travel or lifestyle interfering with dosing

VI. Management: Step 2

  1. Overall Approach
    1. Medication management is in combination with non-medication interventions (including psychotherapy)
    2. Trial each medication for at least 8 to 12 weeks
    3. Reassess initially every 1 to 2 weeks while titrating medication doses
    4. Later, reassess every 4 to 8 weeks
  2. Factors impacting medication selection
    1. Medication Cost
    2. Adverse Effects
    3. Major Depression Severity
    4. Management Urgency
    5. Pharmacogenetics
      1. Variable efficacy in improving Major Depression outcomes
      2. Wang (2023) BMC Psychiatry 23(1): 334 [PubMed]
  3. Consider alternative Antidepressant
    1. Indications
      1. Little or no response to Antidepressant at 8 to 12 weeks of optimal dosing
      2. Adverse effects limit continued use, adequate dosing or compliance
      3. Single medication therapy is preferred by patient to reduce cost and risk of adverse effects
    2. Consider switching from one SSRI to another
    3. Consider switching from an SSRI to a unique Antidepressant class
      1. Mirtazapine (Remeron)
      2. SNRI: Venlafaxine (Effexor), Duloxetine
    4. Protocol for cross-tapering to a new SSRI
      1. First 5-7 days
        1. Cut dose of agent 1 to 50%
        2. Start low dose of agent 2
          1. Delay start of new agent when switching from Fluoxetine (Prozac) due to very long half life
      2. Next
        1. Stop agent 1
        2. Increase dose of agent 2
      3. Example: Celexa to Lexapro over 5 days
        1. Decrease Celexa 40 to 20 and then stop
        2. Start Lexapro 5 mg, then increase to 10 mg
      4. Example: Paxil to Zoloft over at least 7 days
        1. Decrease Paxil 20 to 10 and then stop
        2. Start Zoloft 25 mg, then increase to 50 mg
        3. Paroxetine taper often needs longer duration
  4. Consider Augmenting current Antidepressant regimen
    1. Indications
      1. Partial response to first Antidepressant (intended to be continued)
      2. Desire for faster response rate with augmentation (in contrast to delays with a new single agent)
    2. Augment Selective Serotonin Reuptake Inhibitor (SSRI)
      1. Add Bupropion (Wellbutrin)
        1. Consider in comorbid Fatigue or Antidepressant Induced Sexual Dysfunction
      2. Add SNRI (Venlafaxine, Duloxetine)
        1. Risk of Serotonin Syndrome
        2. Consider in comorbid anxiety
      3. Add Miratazapine (Remeron)
        1. Consider in comorbid Insomnia or Nausea
      4. Add Buspirone (Buspar)
        1. Dosing 15 to 30 mg orally daily
        2. Consider in comorbid anxiety
        3. Variable evidence, with some studies demonstrating no benefit
      5. Add Tricyclic Antidepressant (e.g. Amitriptyline, Desipramine, Nortriptyline)
        1. Use at low dose (25 to 50 mg at bedtime)
        2. Consider in comorbid Insomnia, Headaches or neuropathic pain
        3. Tricyclic Antidepressant Overdose risk
      6. Add Trazodone
        1. Consider in comorbid Insomnia
    3. Atypical Antipsychotics at low dose (however associated with other adverse effects)
      1. See Atypical Antipsychotics for adverse effects
      2. Aripiprazole (Abilify) 2 to 15 mg/day
        1. Preferred of the Atypical Antipsychotics for augmentation due to cost, tolerability
      3. Brexpiprazole (Rexulti) 0.5 to 3 mg daily
      4. Cariprazine (Vraylar) 0.5 to 4.5 mg daily
      5. Olanzapine (Zyprexa) 2.5 to 10 mg daily
        1. Limited evidence for use
      6. Quetiapine (Seroquel) 150 to 300 mg daily
      7. Risperidone (Risperdal) 0.25 to 3 mg daily
      8. Ziprasidone 20 to 80 mg twice daily
    4. Agents used by Psychiatrists to augment therapy (response to these agents is often rapid within 10 days)
      1. Lithium
        1. Dosing 300 to 600 mg daily in divided doses (blood levels 0.4 to 0.8 mEq/L)
        2. Consider if associated Suicidality
        3. Requires close monitoring including levels
      2. Liothyronine (Cytomel, T3)
        1. Dosing 25-50 mcg daily
        2. Similar efficacy to Lithium in refractory depression
        3. May increase nervousness and anxiety
      3. Methylphenidate (Ritalin)
        1. Dosing 10 to 15 mg daily
        2. Consider in comorbid apathy and Fatigue
      4. Pindolol (Visken)
        1. Dosing 2.5 to 7.5 mg daily
      5. Esketamine (Spravato)
        1. Administered 56 to 84 mg intranasally twice weekly for 4 weeks, then every 1-2 weeks
        2. Monitor for 2 hours after each dose (for Hypertension, dissociation, sedation)
        3. Must be given at hospital or clinic within designated REMS program
      6. Ketamine
        1. Infused 0.5 mg/kg IV over 40 minutes for 2 to 3 times weekly
        2. Requires infusion facility and risk of emergence reaction (see Ketamine)
        3. May decrease Suicidal Ideation
    5. Psychedelics
      1. Various Psychedelics have been recommended for treatment refractory depression but evidence is limited
      2. One study found high dose Psilocybin to be slightly better than Placebo
        1. Same study found no benefit with MDMA, LSD or ayahuasca
        2. Hsu (2024) BMJ 386: e078607 [PubMed]

VII. Management: Step 3

  1. Consider Electroconvulsive Therapy

VIII. References

  1. (2023) Presc Lett 30(9): 51-2
  2. Ables (2003) Am Fam Physician 67(3):547-4 [PubMed]
  3. Bridges (1995) Br J Hosp Med 54:501-6 [PubMed]
  4. Cadieux (1998) Am Fam Physician 58(9):2059-62 [PubMed]
  5. Davies (2019) Cochrane Database Syst Rev 12(12):CD010557 +PMID: 31846068 [PubMed]
  6. Gaddey (2024) Am Fam Physician 109(5): 410-6 [PubMed]
  7. Little (2009) Am Fam Physician 80(2):167-72 [PubMed]
  8. Preston (2013) Curr Psychiatry Rep15(7):370 [PubMed]
  9. Ruhe (2006) J Clin Psychiatry 67:1836-1855 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Refractory Depression Management." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Ontology: Major Depressive Disorder (C1269683)

Definition (MSH) Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.
Definition (PSY) Affective disorder marked by dysphoric mood, inactivity, lack of interest, insomnia, feelings of worthlessness, diminished ability to think, and thoughts of suicide. Use DEPRESSION (EMOTION) for nonclinical depression.
Definition (CSP) one or more periods of depression in the absence of history of manic or hypomanic episodes; chronic type lasts 2 or more years; melancholic type is more severe, has vegetative signs, and responds well to somatic therapy.
Concepts Mental or Behavioral Dysfunction (T048)
MSH D003865
ICD10 F32.9
SnomedCT 370143000, 35489007
English Disorder, Major Depressive, Disorders, Major Depressive, Major Depressive Disorders, MDD, MAJOR DEPRESSIVE DISORDER, DEPRESSIVE DIS MAJOR, MAJOR DEPRESSIVE DIS, Major depressive disorder NOS, Major depressive illness, Major depression NOS, Depressive Disorder, Major [Disease/Finding], major depressive illness, major depressive disorder, major depression, Major depressive disorder (diagnosis), Major depression, Major depressive disorder (disorder), Major depressive disorder, Major depression, NOS, Major depressive disorder, NOS, Depressive Disorder, Major, Depressive Disorders, Major, Major Depressive Disorder, Major Depression
Dutch depressieve ziekte, depressieve stoornis NAO, major depression, Depressieve stoornis, ernstige, Ernstige depressieve stoornis, Involutiepsychose, Melancholie, involutionele, Parafrenie, involutionele, Psychose, involutionele, Involutiedepressie, Involutionele depressie
French Syndrome dépressif majeur SAI, Épisode dépressif majeur, Dépression grave, Grave dépression, Dépression majeure, Trouble dépressif majeur
German Major Depression NNB, schwere depressive Krankheit, Endogene Depression, Involutionsdepression, Melancholie, Involutions-, Paraphrenie, Involutions-, Psychose, Involutions-, Depressive Störung, majore, Majore depressive Störung
Italian Depressione maggiore NAS, Malattia depressiva maggiore, Depressione maggiore, Disturbo depressivo maggiore
Portuguese Doença depressiva major, Perturbação depressiva major NE, Depressão grave, Transtorno Depressivo Maior
Spanish Trastorno depresivo mayor NEOM, Enfermedad depresiva mayor, depresión mayor, trastorno depresivo mayor (trastorno), trastorno depresivo mayor, Depresión mayor, Trastorno Depresivo Mayor
Japanese 大うつ病ＮＯＳ, ｵｵｳﾂﾋﾞｮｳ, ﾀﾞｲｳﾂﾋﾞｮｳ, ﾀﾞｲｳﾂﾋﾞｮｳNOS, うつ病-退行期, 大うつ病性障害, 大鬱病, うつ病-更年期, 大うつ病, 初老期うつ病, 更年期うつ病, 更年期鬱病, 精神病-更年期, 退行期うつ病, 退行期パラフレニー, 退行期メランコリア, 退行期精神病, 鬱病-更年期, パラフレニー-退行期, 更年期うつ状態, 更年期メランコリー, 更年期精神病, 更年期鬱状態, 精神病-退行期, 退行期鬱病
Swedish Involutionsdepression
Czech psychóza involuční, deprese involuční, depresivní porucha unipolární, melancholie involuční, parafrenie involuční, Velké depresivní onemocnění, Velká deprese, Velká depresivní porucha NOS
Finnish Laaja-alainen masentuneisuushäiriö
Russian DEPRESSIVNOE RASSTROISTVO TIAZHELOE, DEPRESSIIA INVOLIUTSIONNAIA, MELANKHOLIIA INVOLIUTSIONNAIA, PSIKHOZ INVOLIUTSIONNYI, PARAFRENIIA INVOLIUTSIONNAIA, ДЕПРЕССИВНОЕ РАССТРОЙСТВО ТЯЖЕЛОЕ, ДЕПРЕССИЯ ИНВОЛЮЦИОННАЯ, МЕЛАНХОЛИЯ ИНВОЛЮЦИОННАЯ, ПАРАФРЕНИЯ ИНВОЛЮЦИОННАЯ, ПСИХОЗ ИНВОЛЮЦИОННЫЙ
Polish Wielkie zaburzenie depresyjne, Zaburzenie depresyjne wielkie, Ciężkie zaburzenie depresyjne, Depresja wielka, Parafrenia inwolucyjna, Depresja głęboka, Epizod depresji dużej, Depresja inwolucyjna
Hungarian Major depressiós betegség, Major depressio, Major depressiós zavar k.m.n.
Norwegian Depresjon, alvorlig, Markert depresjon, Depresjon, markert, Alvorlig depresjon, Markant depressiv forstyrrelse
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Depression

advertisement

2025 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Newsletter | Blog

Footer Site Logo